期刊
CLINICAL JOURNAL OF SPORT MEDICINE
卷 21, 期 1, 页码 31-36出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/JSM.0b013e318205a658
关键词
muscle injury; platelet-rich plasma; autologous plasma; platelet-enriched plasma
Objective: To review the evidence for the clinical utilization of autologous plasma products in the management of muscle strain injuries. Method: Systematic review using EMBASE and MEDLINE (up to March 2010). Results: There is no level 1, 2, and 3 evidence for the use of autologous plasma products in muscle strain injuries. Furthermore, significant methodological limitations impact on the interpretation of the few published studies in this field. Conclusions: Although basic science and the use of recombinant growth factors in animal models support the concept of applying growth factors to acute muscle injuries, it is unclear if this evidence can be directly translated to reflect outcomes from platelet-enriched plasma. There remain a large number of unanswered questions, including the principle questions regarding safety and efficacy, which require appropriate scientific investigation. It is incumbent on sports physicians wishing to enhance athlete care, together with researchers, to search for these answers.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据